RT Journal Article
SR Electronic
T1 Comparison of BinaxNOW™ and SARS-CoV-2 qRT-PCR detection of the Omicron Variant from Matched Anterior Nares Swabs
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.31.22270206
DO 10.1101/2022.01.31.22270206
A1 Landaverde, Lena
A1 Turcinovic, Jacquelyn
A1 Doucette-Stamm, Lynn
A1 Gonzales, Kevin
A1 Platt, Judy
A1 Connor, John H.
A1 Klapperich, Catherine
YR 2022
UL http://medrxiv.org/content/early/2022/02/01/2022.01.31.22270206.abstract
AB The COVID-19 pandemic has increased the use of rapid antigen tests such as the Abbott BinaxNOW™ COVID-19 Antigen Self-Test. In winter of 2021-2022, the omicron variant surge made it quickly apparent that although rapid diagnostic tests (RDTs) are less sensitive than qRT-PCR, the accessibility, ease of use, and rapid read-outs of RDTs made them a sought after and often sold-out item at local suppliers. Here, we sought to qualify the BinaxNOW™ test for use in our university testing program as a method to rule in positive or rule out negative individuals quickly when they sought care at our priority qRT-PCR testing site. To perform this qualification study, we collected matched additional swabs from individuals attending this test site for standard of care qRT-PCR testing. All matched swabs were tested using the BinaxNOW™ RDT. 48 of 110 samples tested positive for SARS-CoV-2. All samples for which genome sequence could be collected were omicron (41). We observed a calculated sensitivity of 52.1%, specificity of 100%, a positive predictive value (PPV) of 100%, and a negative predictive value (NPV) of 72.9% for the BinaxNOW™ tests (n=110). Sensitivity was improved (75.7%) by changing the qRT-PCR positivity threshold from a CT of 40 to a CT of 30. The ROC curve shows that for qRT-PCR positive CT values between 23-40, the BinaxNOW™ test is of limited value diagnostically. Our results suggest that RDT tests could be used to confirm SARS-CoV-2 infection in individuals with substantial viral load, but that a significant fraction of infected individuals would be missed if we used RDT tests exclusively at this time.Competing Interest StatementC.M.K. is co founder of Biosens8, Inc. J.H.C. is a consultant for Cell Signaling Technologies.Funding StatementBoston UniversityAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Boston University Charles River Campus IRB, protocol exemption #6402X.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors